Multiple Myeloma
Conditions
Brief summary
Multiple myeloma remains incurable disease in most patients . Cellular immunotherapy using dendritic cells is emerging as a useful immunotherapeutic modality to treat multiple myeloma. Vax-DC/MM is an potent immunotherapeutic agent generated by dendritic cells loaded with the ultraviolet B-irradiated autologous human myeloma cells. The main purpose of this study is to examine the safety and efficacy of Vax-DC/MM in patients with relapsed or refractory multiple myeloma.
Detailed description
* To create the Vax-DC/MM, myeloma cells will be obtained from the bone marrow of the participants, and leukapheresis will be performed to obtain dendritic cells * Not everyone who participants in this study will be receiving the same dose of study vaccine. A small group of patients will be enrolled into the study and given a certain dose. If they tolerate it, the next group of patients enrolled will received a higher dose. * Before the first injection of Vax-DC, low dose cyclophosphamide will be administered to stimulate immune response. * Participants will be received a certain dose of Vax-DC weekly four times.
Interventions
BIOLOGICALVax-DC/MM
Sponsors
Chonnam National University Hospital
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Relapsed or refractory multiple myeloma who received at least one prior therapy including thalidomide, bortezomib, or lenalidomide-containing regimen * Subjects with measurable disease defined as at least one of the following Serum M-protein ≥ 1.0 g/dL Urine M-protein ≥ 400 mg/24hr * Eastern Cooperative Oncology Group Performance Status ≤ 2 * Hemoglobin ≥ 8 g/dL (≥ 4.96 mol/L): Prior red blood cell transfusion or recombinant human erythropoietin use is allowed. * Absolute neutrophil count (ANC) ≥ 1.0 x 109/L * Aspartate aminotransferase (AST) \< 3 times the upper limit of normal * Alanine aminotransferase (ALT) \< 3 times the upper limit of normal * Subjects (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study
Exclusion criteria
* Smoldering or indolent myeloma * Uncontrolled or severe cardiovascular disease (cardiac ejection fraction\<0.5, Severe conduction disorder ) * Sepsis or current active infection * Pregnancy or breastfeeding * Received other immunotherapy treatment * Clinically significant autoimmune disease * Serious medical or psychiatric illness likely to interfere with participation in this clinical study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participants with adverse events | 1 years | Adverse events were assessed using the National Cancer Institute common toxicity criteria (NCI-CTC) for adverse events version 4.0 every injection of Vax-DC/MM |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Clinical response after completion of Vax-DC/MM injection | 2 year | The International Myeloma Working Group uniform criteria were used to assess the clinical response. |
| Progression free survival | 2 year | Progression free survival was defined as the period from the start of treatment until the end follow-up or death from any cause. |
Countries
South Korea
Contacts
Primary ContactSung-Hoon Jung, M.D
Outcome results
None listed